---
schema_version: "secwatch.filing_event.v1"
accession: "0001438133-21-000194"
form_type: "8-K"
ticker: "TNDM"
cik: "0001438133"
company_name: "TANDEM DIABETES CARE INC"
filed_at: "2021-11-03T23:59:59+00:00"
generated_at: "2026-06-28T13:50:55.096175+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tandem Diabetes Q3 sales $179.6M (+45% YoY); raises FY2021 sales guidance to $685-695M

## Summary
- Q3 sales $179.6M (+45% YoY); net income $5.8M vs loss $9.4M; adjusted EBITDA $26.9M (15% of sales).
- Worldwide pump shipments up 43% to 31,558; international shipments up 209% to 11,262.
- Full-year 2021 sales guidance raised to $685-695M from $670-685M; international guidance raised to $168-173M.
- Cash balance $595M, up $110M since Dec 2020; gross margin improved to 54% from 53%.
- Virtual R&D Day scheduled for December 6, 2021.

## SEC filing metadata
- accession: 0001438133-21-000194
- form_type: 8-K
- ticker: TNDM
- cik: 0001438133
- company_name: TANDEM DIABETES CARE INC
- filed_at: 2021-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438133/000143813321000194/0001438133-21-000194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438133/000143813321000194/tndm-20211103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438133-21-000194
- JSON: https://secwatch.observer/filing/0001438133-21-000194.json
- Plain text: https://secwatch.observer/filing/0001438133-21-000194.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.